Denmark· DK-28105609815
Orencia
A abatacept product containing abatacept, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Abatacept is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AA24 (abatacept), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Abatacept · ATC L04AA24
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abatacept costs, country by country.
Normalised to the WHO defined daily dose (27 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Abatacept · price per daily dose (27 mg)
USD · FX 28 Sept 2026
- CH Switzerland$59.45
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Abatacept
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L04AA24
- ATC class
- Abatacept
- Defined daily dose
- 27 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105609815
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
63 interactions on record for abatacept.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Abatacept · interactions on record
63 records
- 30 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AA24
Abatacept, as other registers publish it.
- PolandOrenciaBristol-Myers Squibb Pharma EEIG
- DenmarkOrenciaBristol-Myers Squibb Pharma EEIG
- FinlandOrenciaAbacus Medicine A/S
- FinlandOrenciaOrifarm Oy
- FinlandOrenciaBristol-Myers Squibb Pharma EEIG
- FinlandOrenciaParanova Oy
- FinlandOrenciaBristol-Myers Squibb Pharma EEIG
- IcelandOrenciaBristol-Myers Squibb Pharma EEIG*
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/560c2e35-3d7a-4322-bcb1-8ab7abc70dc4 GET /v1/drugs/560c2e35-3d7a-4322-bcb1-8ab7abc70dc4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning i fyldt pen",
"source": "dkma",
"strength": "125 mg",
"auth_role": "MOD",
"dk_drugid": "28105609815",
"substance": "Abatacept",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "42117"
}See everything about abatacept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.